• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$20.12 -$0.04 (-0.20%)

REAL-TIME: Last trade at

ViroPharma, Inc.

NASDAQ:VPHM

Jump to this page for:

Related Resources

The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in ViroPharma Incorporated of Class Action Lawsuit and the Deadline of July 17, 2012 to Seek a Lead Plaintiff Position

5/25/2012 by Business Wire

Izard Nobel LLP Announces Class Action Lawsuit Against ViroPharma Incorporated

5/24/2012 by Marketwire

Pomerantz Law Firm Has Filed a Class Action Against ViroPharma Incorporated -- VPHM

5/22/2012 by NASDAQ

Pomerantz Law Firm Has Filed a Class Action Against ViroPharma Incorporated -- VPHM

5/22/2012 by GlobeNewswire

Brower Piven Encourages Investors Who Have Losses in Excess of $500,000 from Investment in ViroPharma Incorporated to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the July 17, 2012 Lead Plaintiff Deadline - VPH

5/22/2012 by StockWatch

Brower Piven Encourages Investors Who Have Losses in Excess of $500,000 from Investment in ViroPharma Incorporated to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the July 17, 2012 Lead Plaintiff Deadline - VPHM

5/22/2012 by GlobeNewswire

ViroPharma To Participate In Two June Healthcare Investor Conferences

5/22/2012 by PR Newswire

Investor Alert: Former Louisiana Attorney General and Kahn Swick & Foti, LLC, Remind Investors with Large Financial Interests of Lead Plaintiff Deadline in Class Action Lawsuit Against ViroPharma Inc.

5/19/2012 by StockWatch

Investor Alert: Former Louisiana Attorney General and Kahn Swick & Foti, LLC, Remind Investors with Large Financial Interests of Lead Plaintiff Deadline in Class Action Lawsuit Against ViroPharma Inc.

5/19/2012 by Business Wire

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ViroPharma Incorporated

5/18/2012 by StockWatch

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ViroPharma Incorporated

5/18/2012 by Business Wire

Buyout Options Gaining a Foothold in Deals Means that More than the Price Is Right

5/17/2012 by Genetic Engineering News

5 Biotech Stocks At Rock Bottom Price With Takeover Possibility

5/11/2012 by Seeking Alpha

ViroPharma Falters, Guides Lower - Analyst Blog

5/2/2012 by Zacks Investment Research

ViroPharma Falters, Guides Lower

5/2/2012 by Zacks Equity Research Analyst Blog

District Court Rejects ViroPharma Motion to Block Vancocin Generics

5/1/2012 by Drug Topics

ViroPharma downgraded to Perform from Outperform at Oppenheimer

5/1/2012 by Theflyonthewall.com

ViroPharma shares can rebound, says Piper Jaffray

5/1/2012 by Theflyonthewall.com

Domino's Pizza, Viropharma Among…

5/1/2012 by FOX - Fox 5 - Washington DC

Domino's Pizza, Viropharma Among Stocks Gapping Down Tuesday

5/1/2012 by FOXBusiness.com

ViroPharma gaps down after results, support is at $19.46

5/1/2012 by Theflyonthewall.com

ViroPharma falls 11.4%

5/1/2012 by Theflyonthewall.com

Viropharma, Inc. (VPHM) Misses Q1 EPS by 5c; Guides FY12 Revs Below Views

5/1/2012 by StreetInsider.com

ViroPharma sees 2012 net U.S. Cinryze sales of $310M-$330M

5/1/2012 by Theflyonthewall.com

ViroPharma sees 2012 R&D and SG&A expenses of $220M-$250M

5/1/2012 by Theflyonthewall.com

ViroPharma sees 2012 worldwide net product sales of $450M-$500M

5/1/2012 by Theflyonthewall.com

ViroPharma reports Q1 EPS 37c, consensus 42c

5/1/2012 by Theflyonthewall.com

ViroPharma Incorporated Reports First Quarter 2012 Financial Results

5/1/2012 by PR Newswire

ViroPharma Vancocin guidance likely to beat expectations, says Oppenheimer

4/30/2012 by Theflyonthewall.com

Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis And United Therapeutics

4/28/2012 by Biocompare

Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics

4/27/2012 by PR Newswire

Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics - Press Releases

4/27/2012 by Zacks Investment Research

ViroPharma Loses Bid for Order Blocking Generic Vancocin

4/24/2012 by Bloomberg.com

ViroPharma’s request to block generic Vancocin denied

4/24/2012 by Philadelphia Business Journal - Philadelphia PA

ViroPharma To Release 2012 First Quarter Financial Results On May 1, 2012

4/23/2012 by PR Newswire

Holzer Holzer & Fistel, LLC Announces Investigation into ViroPharma Incorporated

4/21/2012 by PharmiWeb.com - UK

Holzer Holzer & Fistel, LLC Announces Investigation into ViroPharma Incorporated

4/20/2012 by Business Wire

Generic-Drug Maker May Be On Verge Of Biggest Acquisition

4/20/2012 by Investor's Business Daily

ViroPharma Inks Deal with Prasco

4/17/2012 by Zacks Equity Research Analyst Blog

ViroPharma Inks Deal with Prasco - Analyst Blog

4/17/2012 by Zacks Investment Research
See More Articles...